[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"L'Oreal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641516","evaluation-of-the-efficacy-and-tolerability-of-the-led-mask-with-or-without-the-serum-formula-on-the-signs-of-facial-photodamage--100641516",false,"NCT07661004","Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage .","Evaluation of the Efficacy and Tolerability of the LED Mask With or Without the Serum Formula on the Signs of Facial Photodamage","Inclusion Criteria:\n\n1. Female subjects aged between 35-60y.o\n2. Presenting all skin types\n3. Presenting all phototype according to Fitzpatrick Classification\n4. Sensitive skin (50%) - declarative\n5. Daily user of SPF30 or 50+ for at least 30 days\n6. User or not of LED masks (collected data)\n7. Mask adapted to the shape of the face\n8. Having mild to moderate scores (as indicated) for the items parameters\n9. Subjects willing not to change their face\u002Feyes make-up removal products and habits, and shower habits (e.g. shampoo, shower gel), and make-up products (eyes and mouth) throughout the course of the study.\n10. Subjects willing to use the investigational devices and\u002For products on the face throughout the course of the study period\n11. Subjects taking an effective oral contraception or other methods of contraception for the duration of the study\n12. Written Informed Consent Form to participate in the study\n13. illingness and ability to comply with protocol requirements\n\nExclusion Criteria:\n\n1. Subjects having allergy or sensitivity to LED Light\n2. Subjects having at risk of epilepsy\n3. subject who may have headaches\n4. Subjects having participated in the clinical study using anti-aging formula on the face within at least 3 months preceding the baseline visit\n5. Subjects having used any cosmetic products with exfoliating or astringing allegation on the face within at least 4 weeks preceding the baseline visit\n6. Subject with arterial circulatory disorders in the treated area,\n7. Subjects with sensitivity troubles and pain perception impairment, facial paralysis,\n8. Subjects with degenerative and vascular retinal disease,\n9. Subjects with known problems of scarring or wound healing,\n10. History of photosensitivity or photo allergy\n11. History of chronic viral infections (herpes simplex, ZONA…) and last outbreak within 12 months preceding the baseline visit\n12. Subject having an underlying dermatological disease or conditions on the face, which in the investigator's opinion, could interfere with study evaluation\n13. Subjects with a melanoma history in the family (parents or grandparents)\n14. Subjects undergone the radiotherapy in the treated areas,\n15. Subject having excessive moles, excessive pigmented spots, tattoos, scars, irritated skin, etc. at the test area that could influence the investigation\n16. Subject with a history of surgery to the treatment concerned areas within 6 months preceding the baseline visit\n17. Subject reports (or plans to) sunbath or overexpose to UV-light (mountains sports, phototherapy, tanning salon use…) for aesthetic or therapeutic reason one month before the study start (or during the study).\n18. Subject having modified their cosmetic habits (moisturizing skin care, cleansers, make-up removers, make-up, shower products, shampoo…) during the 2 weeks before baseline visit.\n19. Subject uses or has used any of the medications or topical treatments\u002Fskincare products\u002Fprocedure below without relevant wash-out period before the baseline visit (or is unwilling or unable to accept to follow the wash-out period below during the study)\n\n    \\-","FEMALE","35 Years","60 Years",{"count":20,"type":21},130,"ESTIMATED","INTERVENTIONAL",[24],"NA","Main objective : To evaluate the anti-aging effectiveness of the LED mask alone on at least one studied anti-aging parameters (including some targeted wrinkles) after 3 months versus baseline\n\nSecondary objectives:\n\n* Anti-aging clinical score (radiance, skin tone, fine line, ptose, plumpness, ..)\n* Evaluate the consumer perception (self-evaluation)\n* Tolerance\n* Standardized pictures (all light) and pictures analysis\n* Comparison of effectiveness between the 2 groups (with and without formula",[27,28],"Photodamage of the Face","Anti Aging",[30,31,32,33,34],"WRINKLES","SAFETY","EFFICACY","MASK LED","CONSUMER PERCEPTION","NOT_YET_RECRUITING","2026-06-16",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":21},"2026-09-01",{"date":43,"type":21},"2027-04-01",{"name":45,"class":46},"L'Oreal","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100578609","antidandruff-lotion-mediating-microbiome-rebalance-100578609","NCT06813521","Antidandruff Lotion Mediating Microbiome Rebalance","Evaluation of the Effect of a Lotion on Antidandruff and on Mediating Microbiome Rebalance Versus Vehicle and Reference on Volunteers","Inclusion Criteria:\n\n1. Healthy male or female volunteer;\n2. from 18 to 60 years old;\n3. Skin Phototype (Fitzpatrick): I to IV;\n4. Subject with hair length \\> 2 cm, and preferentially shorter than shoulder length;\n5. Female of childbearing potential, who is not sexually active, or using an effective contraceptive method\\* for at least one month before the beginning of the study, and throughout the study or menopausal woman (with absence of menstruations for less than one year) or post-menopausal woman (with absence of menstruations for more than one year);\n6. Subject exhibiting moderate to severe dandruff status of scalp at screening, pre-inclusion and inclusion visit;\n7. Subject having at inclusion visit Day 0:\n\n   1. total dandruff score (adherent + non-adherent) \\> or = 4.5 (ranging from 0 to 10);\n   2. adherent dandruff score \\> or = 2.5 (ranging from 0 to 5);\n   3. no limit for non-adherent dandruff score (ranging from 0 to 5);\n8. Subject usually using a shampoo 3 times\u002Fweek and willing to have two to three times\u002Fweek shampoos during the course of the study;\n9. Subject agreeing to use only the supplied products during all the study;\n10. Subjects agreeing to have 1 zone of less than 2x2cm2 on the scalp for non-invasive sample taking (swabs);\n11. Subject agreeing to have hair shaved on 1 identified zone (1x0.5cm shaved on the high corner of each zone sampling);\n12. Subject who demonstrate understanding of the study and willingness to participate as evidenced by voluntary written informed consent and have received a signed and dated copy of the informed consent form.\n13. Subject affiliated to a social security or insurance system;\n14. Subject willing to comply to the study requirements;\n15. Subject who is willing not to take part in another clinical study in another investigating center;\n16. Subject who agree to give accurate personal in personal information;\n17. Subject who are able to attend all study visits. \\* The effective contraceptive methods: sexually active female of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intravaginal device, intrauterine device (IUD), condom with spermicide.\n\nExclusion Criteria:\n\nEdit\n\nEligibility Criteria: Inclusions criterias:\n\n1. Healthy male or female volunteer;\n2. from 18 to 60 years old;\n3. Skin Phototype (Fitzpatrick): I to IV;\n4. Subject with hair length \\> 2 cm, and preferentially shorter than shoulder length;\n5. Female of childbearing potential, who is not sexually active, or using an effective contraceptive method\\* for at least one month before the beginning of the study, and throughout the study or menopausal woman (with absence of menstruations for less than one year) or post-menopausal woman (with absence of menstruations for more than one year);\n6. Subject exhibiting moderate to severe dandruff status of scalp at screening, pre-inclusion and inclusion visit;\n7. Subject having at inclusion visit Day 0:\n\n   1. total dandruff score (adherent + non-adherent) \\> or = 4.5 (ranging from 0 to 10);\n   2. adherent dandruff score \\> or = 2.5 (ranging from 0 to 5);\n   3. no limit for non-adherent dandruff score (ranging from 0 to 5);\n8. Subject usually using a shampoo 3 times\u002Fweek and willing to have two to three times\u002Fweek shampoos during the course of the study;\n9. Subject agreeing to use only the supplied products during all the study;\n10. Subjects agreeing to have 1 zone of less than 2x2cm2 on the scalp for non-invasive sample taking (swabs);\n11. Subject agreeing to have hair shaved on 1 identified zone (1x0.5cm shaved on the high corner of each zone sampling);\n12. Subject who demonstrate understanding of the study and willingness to participate as evidenced by voluntary written informed consent and have received a signed and dated copy of the informed consent form.\n13. Subject affiliated to a social security or insurance system;\n14. Subject willing to comply to the study requirements;\n15. Subject who is willing not to take part in another clinical study in another investigating center;\n16. Subject who agree to give accurate personal in personal information;\n17. Subject who are able to attend all study visits. \\* The effective contraceptive methods: sexually active female of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intravaginal device, intrauterine device (IUD), condom with spermicide.\n\nNon-inclusion criterias:\n\n1. Subject with any systemic disorder or skin or scalp disease that would, in the investigator's judgment, significantly affect the interpretation of the study results (e.g. seborrheic dermatitis which shows the syndrome of invasion plaque and\u002For pityriasis amiantacea, atopic dermatitis, eczema or psoriasis);\n2. Female subject who is known to be pregnant or who is intending to become pregnant over the duration of the study;\n3. Female subject who is currently breast-feeding or have been breast-feeding in the 6 months prior to the start of the study;\n4. Male subject with alopecia grade ≥ V according to Hamilton-Norwood patterns, female subject with alopecia grade I, II or III according to Ludwig patterns (Appendix 3);\n5. Subject with frizzy hair influencing the scoring of dandruff;\n6. Subject with significant white hair influencing the scoring of dandruff;\n7. Subject who has skin marks on the scalp that could interfere with the assessments (e.g. pigmentation, tattoo, scarring etc.);\n8. Subject who has used products for the scalp (dyeing, bleaching, permanent waving and straightening …) within the three weeks prior to the study;\n9. Subject who has used anti-dandruff treatment (per os or topical) during the last three weeks before the start of the study;\n10. Subject who has used cosmetic anti-hair loss treatment (per os or topical) during the last three months before the start of the study, or\u002Fand subject who has used medical anti-hair loss treatment (per os or topical, ex: Minoxidil, finasteride, etc…) during the last six months before the start of the study;\n11. Subject with personal history of allergy and\u002For particular reactivity to antidandruff products, and\u002For to cosmetic products containing tensioactive agents (soaps, shower gel, conditioner …), and\u002For to latex;\n12. Subject who has taken any systemic drug containing corticoids, or anti-fungal, or antibiotics, or any prolonged use of topical drug containing corticoids, or anti-fungal, or antibiotics, or any prolonged use of non-steroidal anti-inflammatory, or anti-histaminic within one month prior to the study;\n13. Subject who has taken retinoic acid since less than three months prior to the study;\n14. Subject receiving other medication which, in the opinion of the investigator, will affect either the scientific validity of the study or the subject's wellbeing.\n15. Subject with a history of medical\u002Fsurgical events (or surgical events planned) which, in the opinion of the investigator, will affect either the scientific validity of the study or the subject's wellbeing;\n16. Immunosuppressed subject;\n17. Subject with medical history of skin cancer;\n18. Subject who has started, stopped or changed his\u002Fher hormonal treatment (including contraceptive pill) in the previous one month prior to the study;\n19. Subject practicing regularly water sports and\u002For having sauna sessions;\n20. Subject exposed to the sun or UV rays in an excessive way during the last month prior to the study (according to the investigator);\n21. Subject deprived of liberty by adjunction or by official decision;\n22. Subject who is participating or who has participated to a clinical study for which the exclusion period is not finished;\n23. Subject unable to be contacted by phone;\n24. Subject belonging to the staff of the investigating center.\n\n    \\-",true,"ALL","18 Years",{"count":59,"type":21},120,[24],"Edit Brief Summary: To evaluate the NaP lotion effect to decrease dandruff scoring and microbiome rebalance.\n\nDetailed Description: Dandruff is a common scalp disorder affecting almost half of the population of any gender and ethnicity. Skin microflora, in particular Malassezia genus, plays a key etiological role which was demonstrated in many studies.\n\nMalassezia restricta was found as the major fungal species present on the scalps with or without dandruff; while the two main bacterial species found on the scalp surface were Propionibacterium acnes and Staphylococcus epidermidis. Dandruff seems correlated with a higher incidence of Malassezia restricta and Staphylococcus epidermidis and a lower incidence of Cutibacterium acnes.\n\nAlso, the link between dandruff and a higher level of scalp surface lipoperoxidation has been recently described. In fact, dandruff scalp surface is also characterized by higher amounts of squalene monohydroperoxide (SQOOH) and malondialdehyde. MDA is a late biomarker derived from sebaceous unsaturated free fatty acids. Some bibliographic elements suggest that these lipid biomarkers could trigger dandruff.\n\nThe main objective of that clinical study is to study the effect on dandruff of a leave-on formulation of anti-fungus NaP associated with anti-oxidant VitCG versus vehicle and versus reference leave-on anti-fungus alone Octopirox, all associated with a neutral shampoo.",[63],"Dandruff",[65,66,67],"lotion","antidandruff","microbiome rebalance","RECRUITING","2025-02-03",{"date":71,"type":39},"2025-02-07",{"date":73,"type":39},"2024-09-01",{"date":75,"type":21},"2025-06-01",{"name":45,"class":46},""]